Gyre Therapeutics/$GYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gyre Therapeutics
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Ticker
$GYRE
Sector
Primary listing
Employees
625
Headquarters
Website
GYRE Metrics
BasicAdvanced
$701m
384.00
$0.02
6.92
-
Price and volume
Market cap
$701m
Beta
6.92
52-week high
$11.78
52-week low
$6.57
Average daily volume
80k
Financial strength
Current ratio
5.598
Quick ratio
4.579
Long term debt to equity
0.213
Total debt to equity
0.66
Profitability
EBITDA (TTM)
14.011
Gross margin (TTM)
95.35%
Net profit margin (TTM)
4.31%
Operating margin (TTM)
9.86%
Effective tax rate (TTM)
31.56%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
4.93%
Return on equity (TTM)
8.21%
Valuation
Price to earnings (TTM)
384
Price to revenue (TTM)
5.885
Price to book
6.61
Price to tangible book (TTM)
7.02
Price to free cash flow (TTM)
-751.615
Free cash flow yield (TTM)
-0.13%
Free cash flow per share (TTM)
-0.01
Growth
Revenue change (TTM)
10.24%
Earnings per share change (TTM)
-58.40%
3-year revenue growth (CAGR)
4.46%
3-year earnings per share growth (CAGR)
-12.64%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gyre Therapeutics stock?
Gyre Therapeutics (GYRE) has a market cap of $701M as of May 01, 2026.
What is the P/E ratio for Gyre Therapeutics stock?
The price to earnings (P/E) ratio for Gyre Therapeutics (GYRE) stock is 384 as of May 01, 2026.
Does Gyre Therapeutics stock pay dividends?
No, Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Gyre Therapeutics dividend payment date?
Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Gyre Therapeutics?
Gyre Therapeutics (GYRE) has a beta rating of 6.92. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.